Global X Copper Miners ETF vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Global X Copper Miners ETF trades at $84.38 (market cap $7.10B), while Halozyme Therapeutics Inc. Common Stock trades at $110.94 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Halozyme Therapeutics Inc. Common Stock for 0 Days on average.
| COPX | HALO | |
|---|---|---|
Market Cap | $7.10B | $12.58B |
Volume | 2,871,128 | 2,179,278 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $115.22 |
52-Week Low | $57.43 | $61.63 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $14.49B |
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $83.58, down 3.13% amid bearish technical signals with 15 sell indicators versus 2 buy signals. The ETF faces pressure despite positive copper market fundamentals, with copper prices reaching all-time highs near $6.85 per pound. Recent news highlights copper's critical role in AI infrastructure and electrification trends, though mining equities have underperformed the underlying metal.
The copper shortage narrative supports long-term growth potential, but near-term headwinds include global surplus projections and Federal Reserve policy concerns. COPX offers leveraged exposure to copper prices, with analysts divided between buying dips and cautious holding patterns given valuation concerns and mining operational challenges.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →